I'd include data that will support a partner that has money to fully finance Phase III. In that situation we don't know what data endpoints will peak Bigger Pharma's overall interest. I don't see how the company doesn't get the lung X-rays in the near future - ASAP. It's pertinent information that may also provide a peep hole into how the ever elusive Idiopathic Pulmonary Fibrosis clinical trial results could play out. As hard as it's been to get data thus far, leaving that kind of potentially fruitful data hanging on the vine would be nuts.
<<< a backtrack to move forward >>>
Besides the timing...it's the dilution that kills shareholders. Financing going forward is key. Especially since the company is now in the business of DMT.
News 
Market Data 
Discover 
